Claims
- 1. A method for stimulating the production of interferon in a patient comprising administering to a patient in need of elevated levels of interferon. an effective amount of a pharmaceutical composition selected from the group consisting of:
- (a) the complete ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2 as residues 1 to 51 and a pharmaceutically acceptable carrier;
- (b) the mature ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2 as residues 22 to 511, and a pharmaceutically acceptable carrier;
- (c) the extracellular domain of the ISP polypeptide having the amino acid sequence show%n in SEQ ID NO:2 as residues 22 to 487, and a pharmaceutically acceptable carrier;
- (d) a fragment of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2, wherein said fragment has ISP activity, and a pharmaceutically acceptable carrier:
- (e) the complete ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4 as residues 1 to 530 and a pharmaceutically acceptable carrier;
- (f) the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4 as residues 39 to 506, and a pharmaceutically acceptable carrier;
- (g) the extracellular domain of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4 as residues 39 to 523, and a pharmaceutically acceptable carrier: and
- (h) a fragment of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO4, wherein said fragment has ISP activity, and a pharmaceutically acceptable.
- 2. A method of treating infection in a patient comprising administering to a patient in need of such therapy an effective amount of a pharmaceutical composition selected from the group consisting of:
- (a) the complete ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2 as residues 1 to 511 and a pharmaceutically acceptable carrier;
- (b) the mature ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2 as residues 22 to 511 and a pharmaceutical acceptable carrier;
- (c) the extracellular domain of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2 as residues 22 to 487, and a pharmaceutically acceptable carrier;
- (d) a fragment of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:2, wherein said fragment has ISP activity and a pharmaceutically acceptable carrier;
- (e) the complete ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4 as residues 1 to 530 and a pharmaceutically acceptable carrier;
- (f) the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4 as residues 39 to 506, and a pharmaceutically acceptable carrier;
- (g) the extracellular domain of the ISP polypeptide having the amino aid sequence shown in SEQ ID NO:4 as residues 39 to 523, and a pharmaceutically acceptable carrier; and
- (h) a fragment of the ISP polypeptide having the amino acid sequence shown in SEQ ID NO:4, wherein said fragment has ISP activity, and a pharmaceutically acceptable.
- 3. The method of claim 2, wherein the infection is of viral, bacterial, or parasitic origin.
- 4. The method of claim 3, wherein the infection is of viral origin.
- 5. The method of claim 1, wherein the pharmaceutical composition is (a).
- 6. The method of claim 1, wherein the pharmaceutical composition is (b).
- 7. The method of claim 1, wherein the pharmaceutical composition is (c).
- 8. The method of claim 1, wherein the pharmaceutical composition is (d).
- 9. The method of claim 1, wherein the pharmaceutical composition is (e).
- 10. The method of claim 1, wherein the pharmaceutical composition is (f).
- 11. The method of claim 1, wherein the pharmaceutical composition is (a).
- 12. The method of claim 1, wherein the pharmaceutical composition is (h).
- 13. The method of claim 2, wherein the pharmaceutical composition is (a).
- 14. The method of claim 2, wherein the pharmaceutical composition is (b).
- 15. The method of claim 2, wherein the pharmaceutical composition is (c).
- 16. The method of claim 2, wherein the pharmaceutical composition is (d).
- 17. The method of claim 2, wherein the pharmaceutical composition is (e).
- 18. The method of claim 2, wherein the pharmaceutical composition is (f).
- 19. The method of claim 2, wherein the pharmaceutical composition is (g).
- 20. The method of claim 2, wherein the pharmaceutical composition is (h).
Parent Case Info
This application claims the benefit of the filing date of Provisional Application Ser. No. 60/051,053 filed Jun. 27, 1997, which is herein incorporated by reference in its entirety.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5750383 |
Blissard et al. |
May 1998 |
|
5770192 |
Cayley et al. |
Jun 1998 |
|
5846714 |
Haskill et al. |
Dec 1998 |
|
5871986 |
Boyce |
Feb 1999 |
|
Non-Patent Literature Citations (3)
Entry |
Whitford, M. et al., J. Of Virology, 63(3):1393-1399 (Mar. 1989) |
Genbank entry, Accession No. AAA72760. |
Genbank entry, Accession No. AAA66758. |